Expression of tissue inhibitors of metalloproteinases type 1 and type 2 in the leaflets of explanted bioprosthetic heart valves: a new pathogenetic parallel between structural valve degeneration and calcific aortic stenosis

Objective: to study cellular and lipid infiltration, as well as the expression of tissue inhibitors of metalloproteinases (TIMP) types 1 and 2 in biological prosthetic heart valves (BPHVs) explanted due to dysfunction.

Material and Methods. We examined 17 leaflets from 6 BPHVs, dissected from the aortic and mitral positions during valve replacement. For microscopic analysis, fragments of the BPHV leaflets were frozen and serial sections were made using a cryotome. In order to study cellular infiltration and the degree of degenerative changes in the prosthetic biomaterial, the sections were stained with Gill’s hematoxylin and eosin; Oil Red O stain was used to assess lipid deposition. Immunohistochemistry was used for cell typing and detection of TIMP-1/-2. The stained samples were analyzed by light microscopy.

Results. Cellular and lipid infiltration of xenogeneic tissues was detected in all BPHV flaps studied. Recipient cells coexpressed pan-leukocyte and macrophage markers PTPRC/CD45 and CD68. Positive staining for TIMP-1/-2 co-localized with cell clusters but was absent in acellular sections.

Conclusion. Cells infiltrating xenogeneic BPHV tissues express TIMP-1/-2. This suggests that BPHV immune rejection pathophysiology is partially similar to that of calcific aortic stenosis.

1. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009; 119 (7): 1034–1048. doi: 10.1161/CIRCULATIONAHA.108.778886.

2. Ovcharenko EA, Klyshnikov KYu, Glushkova TV, Nushtaev DV, Kudryavtseva YuA, Savrasov GV. The choosing of the xenopericardial patch for transcatheter heart valve. Medical equipment. 2015; 5: 1–4. [In Russ].

3. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine T et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017; 38 (45): 3382–3390. doi: 10.1093/eurheartj/ehx303.

4. Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG et al. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation. 2018; 137 (4): 388–399. doi: 10.1161/CIRCULATIONAHA.117.030729.

5. Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016; 2: 16006. doi: 10.1038/nrdp.2016.6.

6. Shetty R, Pibarot P, Audet A, Janvier R, Dagenais F, Perron J et al. Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Eur J Clin Invest. 2009; 39 (6): 471–480. doi: 10.1111/j.1365-2362.2009.02132.x.

7. Simionescu A, Simionescu DT, Deac RF. Matrix metalloproteinases in the pathology of natural and bioprosthetic cardiac valves. Cardiovasc Pathol. 1996; 5 (6): 323–332. PMID: 25851789.

8. Cote N, Pibarot P, Clavel MA. Incidence, risk factors, clinical impact, and management of bioprosthesis structural valve degeneration. Curr Opin Cardiol. 2017; 32 (2): 123–129. doi: 10.1097/HCO.0000000000000372.

9. Bosse Y, Miqdad A, Fournier D, Pepin A, Pibarot P, Mathieu P. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet. 2009; 2 (5): 489–498. doi: 10.1161/CIRCGENETICS.108.820795.

10. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J. 2005; 26 (13): 1333–1341. doi: 10.1093/eurheartj/ehi248.

11. Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015; 44–46: 247–254. doi: 10.1016/j.matbio.2015.03.005.

12. Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014; 71 (4): 659–672. doi: 10.1007/s00018-013-1457-3.

13. Bogdanov LA, Kutikhin AG. Optimization of hematoxylin and eosin staining of heart, blood vessels, liver, and spleen. Fundamental and Clinical Medicine. 2019; 4 (4): 70–77. [in Russian]. doi: 10.23946/2500-0764-2019-4-4-70-77.

14. Kostyunin AE, Glushkova TV. The first results of the study of matrix metalloproteinases-1/-2/-9/-12 expression in xenogenic tissues of epoxy-treated bioprosthetic heart valves explanted due to dysfunctions. Russian Journal of Cardiology. 2020; 25 (10): 49–55. doi: 10.15829/1560-4071-2020-3978.

15. Kostyunin A, Mukhamadiyarov R, Glushkova T, Bogdanov L, Shishkova D, Osyaev N et al. Ultrastructural pathology of atherosclerosis, calcific aortic valve disease, and bioprosthetic heart valve degeneration: commonalities and differences. Int J Mol Sci. 2020; 21 (20): E7434. doi: 10.3390/ijms21207434.

16. Lee S, Levy RJ, Christian AJ, Hazen SL, Frick NE, Lai EK et al. Calcification and oxidative modifications are associated with progressive bioprosthetic heart valve dysfunction. J Am Heart Assoc. 2017; 6 (5). pii: e005648. doi: 10.1161/JAHA.117.005648.

17. Di Gregoli K, George SJ, Jackson CL, Newby AC, Johnson JL. Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res. 2016; 109 (2): 318–330. doi: 10.1093/cvr/cvv268.